Erin Wright
Stock Analyst at Morgan Stanley
(4.41)
# 388
Out of 4,996 analysts
229
Total ratings
64.07%
Success rate
13.04%
Average return
Main Sectors:
Stocks Rated by Erin Wright
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MCK McKesson | Maintains: Overweight | $810 → $857 | $760.55 | +12.68% | 9 | Sep 24, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $722 → $765 | $632.22 | +21.00% | 16 | Aug 15, 2025 | |
| NVST Envista Holdings | Maintains: Equal-Weight | $16 → $17 | $20.35 | -16.46% | 9 | Aug 1, 2025 | |
| CVS CVS Health | Maintains: Overweight | $80 → $82 | $75.77 | +8.22% | 5 | Aug 1, 2025 | |
| HUM Humana | Maintains: Equal-Weight | $290 → $277 | $254.95 | +8.65% | 4 | Jul 31, 2025 | |
| ALGN Align Technology | Downgrades: Equal-Weight | $249 → $154 | $126.19 | +22.04% | 23 | Jul 31, 2025 | |
| ELV Elevance Health | Maintains: Overweight | $428 → $316 | $318.61 | -0.82% | 3 | Jul 18, 2025 | |
| PSX Phillips 66 | Maintains: Equal-Weight | $122 → $128 | $139.46 | -8.22% | 1 | Jul 16, 2025 | |
| COR Cencora | Maintains: Equal-Weight | $313 → $330 | $307.00 | +7.49% | 1 | Jul 16, 2025 | |
| CAH Cardinal Health | Maintains: Overweight | $181 → $190 | $153.71 | +23.61% | 12 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $364 → $266 | $191.98 | +38.56% | 2 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $21 → $26 | $38.81 | -33.01% | 23 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $25 | $27.39 | -8.73% | 3 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $379 → $390 | $286.17 | +36.28% | 5 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $3.5 → $3.2 | $2.65 | +20.75% | 12 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 → $13 | $19.61 | -33.71% | 11 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $243 → $238 | $143.50 | +65.85% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $23 | $12.50 | +84.00% | 12 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $145 → $172 | $188.99 | -8.99% | 5 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $69 → $65 | $66.04 | -1.57% | 4 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $587 | $344.08 | +70.60% | 3 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $300 | $280.61 | +6.91% | 4 | Aug 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $39 → $42 | $11.84 | +254.73% | 5 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $282 → $288 | $184.84 | +55.81% | 6 | Jun 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $342 → $352 | $148.56 | +136.94% | 4 | May 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $44 | $2.82 | +1,460.28% | 2 | May 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $178 → $181 | $496.79 | -63.57% | 8 | Mar 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $17 | $50.61 | -66.41% | 6 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $104 → $121 | $39.66 | +205.09% | 7 | Jan 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $556 → $580 | $464.24 | +24.94% | 4 | Jan 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $11.80 | +196.61% | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $181 → $205 | $163.79 | +25.16% | 2 | Jul 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $12 → $11 | $22.59 | -51.31% | 6 | May 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $175 → $157 | $179.56 | -12.56% | 1 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $38 | $27.81 | +36.64% | 1 | May 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $31 → $17 | $4.77 | +256.39% | 1 | Nov 20, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $300 → $308 | $487.44 | -36.81% | 1 | Oct 25, 2017 |
McKesson
Sep 24, 2025
Maintains: Overweight
Price Target: $810 → $857
Current: $760.55
Upside: +12.68%
IDEXX Laboratories
Aug 15, 2025
Maintains: Overweight
Price Target: $722 → $765
Current: $632.22
Upside: +21.00%
Envista Holdings
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $16 → $17
Current: $20.35
Upside: -16.46%
CVS Health
Aug 1, 2025
Maintains: Overweight
Price Target: $80 → $82
Current: $75.77
Upside: +8.22%
Humana
Jul 31, 2025
Maintains: Equal-Weight
Price Target: $290 → $277
Current: $254.95
Upside: +8.65%
Align Technology
Jul 31, 2025
Downgrades: Equal-Weight
Price Target: $249 → $154
Current: $126.19
Upside: +22.04%
Elevance Health
Jul 18, 2025
Maintains: Overweight
Price Target: $428 → $316
Current: $318.61
Upside: -0.82%
Phillips 66
Jul 16, 2025
Maintains: Equal-Weight
Price Target: $122 → $128
Current: $139.46
Upside: -8.22%
Cencora
Jul 16, 2025
Maintains: Equal-Weight
Price Target: $313 → $330
Current: $307.00
Upside: +7.49%
Cardinal Health
Jul 16, 2025
Maintains: Overweight
Price Target: $181 → $190
Current: $153.71
Upside: +23.61%
Jul 10, 2025
Downgrades: Equal-Weight
Price Target: $364 → $266
Current: $191.98
Upside: +38.56%
Jun 25, 2025
Maintains: Equal-Weight
Price Target: $21 → $26
Current: $38.81
Upside: -33.01%
May 9, 2025
Maintains: Overweight
Price Target: $20 → $25
Current: $27.39
Upside: -8.73%
May 5, 2025
Maintains: Overweight
Price Target: $379 → $390
Current: $286.17
Upside: +36.28%
Apr 17, 2025
Maintains: Underweight
Price Target: $3.5 → $3.2
Current: $2.65
Upside: +20.75%
Feb 26, 2025
Maintains: Equal-Weight
Price Target: $14 → $13
Current: $19.61
Upside: -33.71%
Feb 14, 2025
Maintains: Overweight
Price Target: $243 → $238
Current: $143.50
Upside: +65.85%
Dec 17, 2024
Maintains: Overweight
Price Target: $30 → $23
Current: $12.50
Upside: +84.00%
Dec 17, 2024
Upgrades: Overweight
Price Target: $145 → $172
Current: $188.99
Upside: -8.99%
Nov 14, 2023
Maintains: Underweight
Price Target: $69 → $65
Current: $66.04
Upside: -1.57%
Jul 14, 2023
Reiterates: Overweight
Price Target: $587
Current: $344.08
Upside: +70.60%
Aug 22, 2022
Assumes: Overweight
Price Target: $300
Current: $280.61
Upside: +6.91%
Jul 30, 2021
Maintains: Outperform
Price Target: $39 → $42
Current: $11.84
Upside: +254.73%
Jun 18, 2021
Maintains: Outperform
Price Target: $282 → $288
Current: $184.84
Upside: +55.81%
May 28, 2021
Maintains: Neutral
Price Target: $342 → $352
Current: $148.56
Upside: +136.94%
May 11, 2021
Maintains: Outperform
Price Target: $42 → $44
Current: $2.82
Upside: +1,460.28%
Mar 17, 2021
Maintains: Outperform
Price Target: $178 → $181
Current: $496.79
Upside: -63.57%
Feb 26, 2021
Maintains: Neutral
Price Target: $14 → $17
Current: $50.61
Upside: -66.41%
Jan 13, 2021
Maintains: Outperform
Price Target: $104 → $121
Current: $39.66
Upside: +205.09%
Jan 12, 2021
Maintains: Outperform
Price Target: $556 → $580
Current: $464.24
Upside: +24.94%
Jan 5, 2021
Initiates: Neutral
Price Target: $35
Current: $11.80
Upside: +196.61%
Jul 23, 2020
Maintains: Outperform
Price Target: $181 → $205
Current: $163.79
Upside: +25.16%
May 5, 2020
Maintains: Neutral
Price Target: $12 → $11
Current: $22.59
Upside: -51.31%
Apr 2, 2020
Maintains: Outperform
Price Target: $175 → $157
Current: $179.56
Upside: -12.56%
May 9, 2018
Maintains: Outperform
Price Target: $42 → $38
Current: $27.81
Upside: +36.64%
Nov 20, 2017
Maintains: Underperform
Price Target: $31 → $17
Current: $4.77
Upside: +256.39%
Oct 25, 2017
Maintains: Neutral
Price Target: $300 → $308
Current: $487.44
Upside: -36.81%